GeneNova

FOR SAFER, MORE EFFICIACIOUS AND ACCESSIBLE AAV GENE THERAPY

Our vision is to innovate AAV bioproduction and provide a platform aimed at order of magnitudes improvement compared to state-of-art today. We do this by combining expertise from experts of different areas aligning world-leading Swedish faculty within cellbiology, pharmacology, systems biology, neurology, drug discovery, industrial biotechnology, and mathematics with Swedish global commercial technology, service providers and biopharmaceutical companies to one goal – to enable the sustainable access to curative treatment by AAV for the patient. GeneNova is funded by partner companies and VINNOVA Sweden’s innovation agency  2021-2026.

Coordinator: KTH Royal Inst Technology.

Partners: Alfa Laval, AstraZeneca, Biotage, Combigene, Karolinska Institutet, Uppsala University, Vironova, Ziccum

Our vision is to innovate AAV bioproduction and provide a platform aimed at order of magnitudes improvement compared to state-of-art today. We do this by combining expertise from experts of different areas aligning world-leading Swedish faculty within cellbiology, pharmacology, systems biology, neurology, drug discovery, industrial biotechnology, and mathematics with Swedish global commercial technology, service providers and biopharmaceutical companies to one goal – to enable the sustainable access to curative treatment by AAV for the patient. GeneNova is funded by partner companies and VINNOVA Sweden’s innovation agency  2021-2026.

PROJECTS

  • Automation of plasmid preparation
  • Vector engineering
  • Cell line engineering
  • Bioprocess engineering
  • Gentle separation
  • Downstream purification
  • Gentle formulation
  • In vitro and in vivo PoC
  • Machine learning for improved HTP
  • Electron Microscopy and NGS sequencing

Contact: Prof. Johan Rockberg KTH

Website: www.genenova.org

Regulatory Guide

What are the processes in getting ATMPs manufactured and into clinical trial?

Swelife-ATMP on Gene Therapy

Opportunities and challenges for Sweden to become internationally leading in the field of gene therapy,